The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice

Journal of Nutritional Biochemistry

Volumn 23, Issue 10, 2012, Pages 1230-1237

  Ye, Lan ^a   Chan, Franky L ^b   Chen, Shiuan ^c   Leung, Lai K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase; Breast cancer cells; Hesperetin

Indexed keywords

APIGENIN; AROMATASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; ESTROGEN; HESPERETIN; MESSENGER RNA; NARINGENIN; PROTEIN BCL XL; PROTEIN PS2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER INHIBITION; CELL STRAIN MCF 7; CELL TRANSPLANTATION; CONTROLLED STUDY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARIECTOMY; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BCL-X PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; CITRUS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P57; ESTRADIOL; ESTROGENS; FEMALE; HESPERIDIN; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; OVARIECTOMY; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CITRUS; MUS;

EID: 84866323013     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.07.003     Document Type: Article

References (43)

1. Colditz G.A. Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. J Womens Health 1999, 8:347-357.
2. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
3. Yoshidome K., Shibata M.A., Couldrey C., Korach K.S., Green J.E. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res 2000, 60:6901-6910.
4. Liehr J.G., Fang W.F., Sirbasku D.A., Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986, 24:353-356.
5. Li J.J., Li S.A. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 1987, 46:1858-1863.
6. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998, 19:1-27.
7. Leung L.K., Wang T.T. Paradoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7. Br J Cancer 1999, 81:387-392.
8. Sommer S., Fuqua S.A. Estrogen receptor and breast cancer. Semin Cancer Biol 2001, 11:339-352.
9. Kudachadkar R., O'Regan R.M. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005, 55:145-163.
10. Miller W.R., Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001, 79:93-102.
11. Santner S.J., Chen S., Zhou D., Korsunsky Z., Martel J., Santen R.J. Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J Steroid Biochem Mol Biol 1993, 44:611-616.
12. Yue W., Santner S.J., Masamura S., Wang J.P., Demers L.M., Hamilton C., et al. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 1998, 49(Suppl 1):S1-S7. discussion S33-7.
13. Lee K.M., Abel J., Ko Y., Harth V., Park W.Y., Seo J.S., et al. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br J Cancer 2003, 88:675-678.
14. Hirose K., Matsuo K., Toyama T., Iwata H., Hamajima N., Tajima K. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev 2004, 13:1407-1411.
15. Benavente-Garcia O., Castillo J., Alcaraz M., Vicente V., Del Rio J.A., Ortuno A. Beneficial action of citrus flavonoids on multiple cancer-related biological pathways. Curr Cancer Drug Targets 2007, 7:795-809.
16. Manthey J.A., Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem 2002, 50:5837-5843.
17. So F.V., Guthrie N., Chambers A.F., Moussa M., Carroll K.K. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996, 26:167-181.
18. Guthrie N., Carroll K.K. Inhibition of mammary cancer by citrus flavonoids. Adv Exp Med Biol 1998, 439:227-236.
19. Aranganathan S., Panneer Selvam J., Nalini N. Hesperetin exerts dose dependent chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis. Invest New Drugs 2008.
20. Choi E.J. Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: involvement of CDK4 and p21. Nutr Cancer 2007, 59:115-119.
21. Mak P., Leung Y.K., Tang W.Y., Harwood C., Ho S.M. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 2006, 8:896-904.
22. Choi E.J., Kim G.H. Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J Clin Biochem Nutr 2009, 44:260-265.
23. Chen D., Landis-Piwowar K.R., Chen M.S., Dou Q.P. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res 2007, 9:R80.
24. Jeong H.J., Shin Y.G., Kim I.H., Pezzuto J.M. Inhibition of aromatase activity by flavonoids. Arch Pharm Res 1999, 22:309-312.
25. van Meeuwen J.A., Nijmeijer S., Mutarapat T., Ruchirawat S., de Jong P.C., Piersma A.H., et al. Aromatase inhibition by synthetic lactones and flavonoids in human placental microsomes and breast fibroblasts - a comparative study. Toxicol Appl Pharmacol 2008, 228:269-276.
26. Saarinen N., Joshi S.C., Ahotupa M., Li X., Ammala J., Makela S., et al. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. J Steroid Biochem Mol Biol 2001, 78:231-239.
27. Yue W., Zhou D., Chen S., Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994, 54:5092-5095.
28. Zhou D.J., Pompon D., Chen S.A. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990, 50:6949-6954.
29. Grube B.J., Eng E.T., Kao Y.C., Kwon A., Chen S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J Nutr 2001, 131:3288-3293.
30. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
31. Wang Y., Man Gho W., Chan F.L., Chen S., Leung L.K. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br J Nutr 2008, 99:303-310.
32. Yue W., Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol 1993, 44:671-673.
33. Walle U.K., Walle T. Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements. Drug Metab Dispos 2002, 30:564-569.
34. Doostdar H., Burke M.D., Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000, 144:31-38.
35. Hiyama H., Iavarone A., LaBaer J., Reeves S.A. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 1997, 14:2533-2542.
36. Foster J.S., Henley D.C., Bukovsky A., Seth P., Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 2001, 21:794-810.
37. Lee Y., Renaud R.A., Friedrich T.C., Gorski J. Estrogen causes cell death of estrogen receptor stably transfected cells via apoptosis. J Steroid Biochem Mol Biol 1998, 67:327-332.
38. Perillo B., Sasso A., Abbondanza C., Palumbo G. 17beta-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000, 20:2890-2901.
39. Ye L., Gho W.M., Chan F.L., Chen S., Leung L.K. Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase. Int J Cancer 2009, 124:1028-1036.
40. Wang Y., Chan F.L., Chen S., Leung L.K. The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase. Life Sci 2005, 77:39-51.
41. Wang Y., Lee K.W., Chan F.L., Chen S., Leung L.K. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci 2006, 92:71-77.
42. Matsumoto H., Ikoma Y., Sugiura M., Yano M., Hasegawa Y. Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J Agric Food Chem 2004, 52:6653-6659.
43. Habauzit V., Nielsen I.L., Gil-Izquierdo A., Trzeciakiewicz A., Morand C., Chee W., et al. Increased bioavailability of hesperetin-7-glucoside compared with hesperidin results in more efficient prevention of bone loss in adult ovariectomised rats. Br J Nutr 2009, 102:976-984.